# PG AI

DNA-Aware Health Powered By AI

Enabling Safe & Efficient Drug Therapy Through Drug-Drug Interactions and Multi-Omics Data Integration

Partners

InterSystems®
Creative data technology

AI Collaboration

Microsoft   Google   ∞ Meta   amazon

2024

PGxAI: Leading AI-Driven Pharmacogenetics Platform backed by InterSystems Working in Collaboration with AI Experts from Microsoft Google, Meta & Amazon

1 **PGxAI is the most advanced AI-powered PGx platform** to redefine precision medicine through the most comprehensive coverage of drugs (>730 substances) and proprietary algorithms built on vast amounts of real-world data to solve drug selection, dosage personalization, and identification of clinically relevant drug-drug interactions.

2 **Largest database** including more than **5 billion elements** with a pre-trained and patented ML-classifier (XGBoost) (accuracy, sensitivity & specificity >89%).

3 **Prescription drug market** (market size $750bn) increasingly disrupted by pharmacogenomics (market size $9bn). In Q2 2023, The Lancet study showed that PGx reduces the frequency and severity of ADRs by >30%. Insurance companies and Medicare are gradually starting to reimburse.

4 **B2B2C business model:** implementing PGx in diagnostic laboratories (Sequencing.com, DDNA, ClarityX), hospitals (MENA, Mayo Clinic), federal organizations (Veteran Affairs) through InterSystems.

5 **Distinguished Management Team** with exceptional track record in pharmacogenomics research (CEO & Co-Founder Michael Zastrozhin, MD, PhD, MPH, ex-UCSF, H-index 34, >25k citations) and development (VP of DO Alex Raud, >15 years at Intel/Apple) with exits (Executive Chairman & Co-Founder Allan Gobbs, 9 exits, including 5 IPOs).

6 **Advisory Board** includes key opinion leaders in precision medicine with backgrounds from Thermo Fisher, GE Healthcare, Tempus AI, Quest Diagnostics, Abbott, etc.

7 **PGxAI is developed in strategic partnership with InterSystems** ([PGxAI among 204 most valuable partners](#)), being a leading partner in the use of AI solutions in precision medicine. PGxAI is building strong collaborations with Microsoft, Google, Meta, and Amazon.

Distinguished Management Team with 9 Exits, Incl. 5 IPOs & Exceptional Track Record in Pharmacogenomics And Diagnostics Sales

Michael Zastrozhin, MD
CEO & Co-Founder

MD PhD, Bioengineering and
Therapeutical Sciences at UCSF

Allan Gobbs
Executive Chair & Co-Founder

Venture Investor,
5 NASDAQ IPOs + 4 M&As

Alex Raud
VP of Development

Architect, Product Manager
at Intel

Russ Altman
Scientific Advisor

Full Professor at
Stanford University

Joydeep Bhattacharyya
Business Advisor

Ex-Director Innovation, Strategy
& Product at GE Healthcare

Data
Scientists
Designers

ML-Engineers

Bioinformaticians

Full-Stack
Developers

Emily Chen
Scientific Clinical Advisor

Senior Director at Thermo Fisher
Precision Medicine Science Center

Dave Vigerust
Scientific Lab Advisor

Chief Scientific Officer at
Spectrum Solutions

Nisha Talagala
Scientific ML/AI Advisor

Founder and CEO at
Pyxeda.AI

Lisa Brown
Scientific PGx Advisor

Senior Medical Science Liaison at
Tempus Labs

Terry Robins
Business Advisor

Senior Director Clinical Affairs
at Abbott

PG AI

DNA-Aware Health Powered By AI

730 Moreno Ave
Palo Alto, CA, 94303

Allan Gobbs, Executive Chairman
ag@pgx.ai